Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 20Lymphoma 6Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphomatoid Papulosis 3Lymphoma, Large-Cell, Anaplastic 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoblastic Lymphadenopathy 2Hematologic Diseases 2Enteropathy-Associated T-Cell Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 21pomalidomide 18Lenalidomide 18Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8Carboplatin 8obinutuzumab 7cemiplimab 7Drug Therapy 7Bevacizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Brentuximab Vedotin × 1 year × Clear all
NCT01909934 2025-09-19

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Takeda

Phase 4 Completed
50 enrolled 22 charts
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡